Major CVOTs have shown how GLP-1 receptor agonists reduce the risk of major adverse cardiovascular events and are now used in the treatment of obesity, and they show a number of positive biological effects [36]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.